CN107278205A - 用作抗癌药的取代的核苷衍生物 - Google Patents

用作抗癌药的取代的核苷衍生物 Download PDF

Info

Publication number
CN107278205A
CN107278205A CN201680011823.1A CN201680011823A CN107278205A CN 107278205 A CN107278205 A CN 107278205A CN 201680011823 A CN201680011823 A CN 201680011823A CN 107278205 A CN107278205 A CN 107278205A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
hydroxyl
cancer
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680011823.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·塔特洛克
I·J·麦卡尔平
M·B·特兰-杜布
E·Y·芮
M·J·威思
R·A·孔普夫
M·A·麦克蒂古
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN107278205A publication Critical patent/CN107278205A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
CN201680011823.1A 2015-02-24 2016-02-15 用作抗癌药的取代的核苷衍生物 Pending CN107278205A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US62/119,932 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US62/213,801 2015-09-03
US201662279209P 2016-01-15 2016-01-15
US62/279,209 2016-01-15
PCT/IB2016/050803 WO2016135582A1 (en) 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
CN107278205A true CN107278205A (zh) 2017-10-20

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680011823.1A Pending CN107278205A (zh) 2015-02-24 2016-02-15 用作抗癌药的取代的核苷衍生物

Country Status (29)

Country Link
US (1) US10428104B2 (cg-RX-API-DMAC7.html)
EP (1) EP3262057B1 (cg-RX-API-DMAC7.html)
JP (1) JP6584521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170119705A (cg-RX-API-DMAC7.html)
CN (1) CN107278205A (cg-RX-API-DMAC7.html)
AU (2) AU2016225133B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017017396A2 (cg-RX-API-DMAC7.html)
CA (1) CA2921314A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002155A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008403A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170384A (cg-RX-API-DMAC7.html)
CU (1) CU20170105A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000195A (cg-RX-API-DMAC7.html)
EA (1) EA031895B1 (cg-RX-API-DMAC7.html)
ES (1) ES2792899T3 (cg-RX-API-DMAC7.html)
GT (1) GT201700189A (cg-RX-API-DMAC7.html)
IL (1) IL253637A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017010844A (cg-RX-API-DMAC7.html)
NI (1) NI201700095A (cg-RX-API-DMAC7.html)
PE (1) PE20171449A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501413A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201706050WA (cg-RX-API-DMAC7.html)
SV (1) SV2017005514A (cg-RX-API-DMAC7.html)
TN (1) TN2017000357A1 (cg-RX-API-DMAC7.html)
TW (1) TWI622595B (cg-RX-API-DMAC7.html)
UA (1) UA118315C2 (cg-RX-API-DMAC7.html)
UY (1) UY36564A (cg-RX-API-DMAC7.html)
WO (1) WO2016135582A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201705092B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111542525A (zh) * 2017-10-26 2020-08-14 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
CN112679505A (zh) * 2020-12-25 2021-04-20 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
CN114127072A (zh) * 2019-03-25 2022-03-01 加利福尼亚技术学院 Prmt5抑制剂及其用途

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
BR112019006414A2 (pt) * 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
SG11201907607VA (en) 2017-02-27 2019-09-27 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
MA49840A (fr) * 2017-08-09 2020-06-17 Prelude Therapeutics Inc Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
MX2020005944A (es) * 2017-12-08 2020-08-24 Janssen Pharmaceutica Nv Analogos espirobiciclicos novedosos.
CR20200263A (es) 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CA3092357A1 (en) * 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20220160713A1 (en) * 2019-02-13 2022-05-26 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
WO2020206299A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
CR20220010A (es) 2019-06-10 2022-05-13 Lupin Ltd Inhibidores de prmt5
PH12021553075A1 (en) 2019-06-12 2023-09-11 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
SI4299135T1 (sl) 2019-06-18 2025-12-31 Pfizer Inc. Benzizoksazolni sulfonamidni derivati
CA3154566A1 (en) 2019-09-18 2021-03-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
GEP20247638B (en) 2019-10-22 2024-07-10 Lupin Ltd Pharmaceutical combination of prmt5 inhibitors
EP4069698A1 (en) 2019-12-03 2022-10-12 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
IL300555A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK inhibitor
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CA3226714A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
WO2023017152A1 (en) * 2021-08-13 2023-02-16 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
WO2026008533A1 (en) 2024-07-01 2026-01-08 Janssen Pharmaceutica Nv Prmt5 inhibitors for treating adenomas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492348B1 (en) * 1998-06-23 2002-12-10 Smithkline Beecham Corporation Adenosine derivatives
US20040043960A1 (en) * 2002-08-15 2004-03-04 Jeff Zablocki Partial and full agonists of A1 adenosine receptors
CN107580602A (zh) * 2015-05-04 2018-01-12 伊莱利利公司 5’‑取代的核苷类似物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
WO2013009735A1 (en) * 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8575119B2 (en) * 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AU2016301188A1 (en) * 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492348B1 (en) * 1998-06-23 2002-12-10 Smithkline Beecham Corporation Adenosine derivatives
US20040043960A1 (en) * 2002-08-15 2004-03-04 Jeff Zablocki Partial and full agonists of A1 adenosine receptors
CN107580602A (zh) * 2015-05-04 2018-01-12 伊莱利利公司 5’‑取代的核苷类似物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTA E. MÜLLER ET AL.: "Recent developments in adenosine receptor ligands and their potential as novel drugs", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *
DONGHANG CHENG ET AL.: "Small Molecule Regulators of Protein Arginine Methyltransferases", 《THEJOURNAL OFBIOLOGICAL CHEMISTRY》 *
KANCHAN DEVKOTA ET AL.: "Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2", 《ACS MEDICINAL CHEMISTRY LETTERS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111542525A (zh) * 2017-10-26 2020-08-14 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
CN111542525B (zh) * 2017-10-26 2023-06-27 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
CN114127072A (zh) * 2019-03-25 2022-03-01 加利福尼亚技术学院 Prmt5抑制剂及其用途
CN114127072B (zh) * 2019-03-25 2024-10-11 加利福尼亚技术学院 Prmt5抑制剂及其用途
CN112679505A (zh) * 2020-12-25 2021-04-20 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法

Also Published As

Publication number Publication date
UY36564A (es) 2016-09-30
AU2016225133B2 (en) 2018-11-29
MX2017010844A (es) 2017-12-07
ZA201705092B (en) 2019-06-26
WO2016135582A1 (en) 2016-09-01
JP6584521B2 (ja) 2019-10-02
IL253637A0 (en) 2017-09-28
EA031895B1 (ru) 2019-03-29
UA118315C2 (uk) 2018-12-26
CU20170105A7 (es) 2017-10-05
TW201643176A (zh) 2016-12-16
CA2921314A1 (en) 2016-08-24
EA201791563A1 (ru) 2018-01-31
JP2018510850A (ja) 2018-04-19
TWI622595B (zh) 2018-05-01
EP3262057A1 (en) 2018-01-03
ES2792899T3 (es) 2020-11-12
US10428104B2 (en) 2019-10-01
CL2017002155A1 (es) 2018-05-11
BR112017017396A2 (pt) 2018-04-03
TN2017000357A1 (en) 2019-01-16
DOP2017000195A (es) 2017-10-15
CO2017008403A2 (es) 2017-10-31
PH12017501413A1 (en) 2018-01-29
EP3262057B1 (en) 2020-04-15
PE20171449A1 (es) 2017-10-02
NI201700095A (es) 2017-10-31
KR20170119705A (ko) 2017-10-27
AU2016225133A1 (en) 2017-08-10
CR20170384A (es) 2017-11-16
US20160244475A1 (en) 2016-08-25
AU2018278842A1 (en) 2019-01-03
SG11201706050WA (en) 2017-09-28
GT201700189A (es) 2019-06-10
SV2017005514A (es) 2018-04-11

Similar Documents

Publication Publication Date Title
TWI622595B (zh) 充當抗癌劑的經取代核苷衍生物
CN109890797B (zh) 可用作抗癌剂的取代的碳核苷衍生物
CN106999479B (zh) 可用作sumo活化酶抑制剂的杂芳基化合物
KR20150103285A (ko) 피리미돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도
HK1241886A1 (en) Substituted nucleoside derivatives useful as anticancer agents
WO2023116748A1 (zh) 取代的杂芳基化合物及其组合物和用途
OA18433A (en) Substituted nucleoside derivatives useful as anticancer agents
WO2016204135A1 (ja) 5員ヘテロ環誘導体
HK40008995A (en) Substituted carbonucleoside derivatives useful as anticancer agents
HK40104978A (en) Carboxy-benzimidazole glp-1r modulating compounds
HK40008995B (en) Substituted carbonucleoside derivatives useful as anticancer agents
OA20884A (en) Cystic fibrosis transmembrane conductance regulator modulating agents.
NZ748652B2 (en) Substituted carbonucleoside derivatives useful as anticancer agents
HK40012363A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
TW201702248A (zh) 6員雜環衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241886

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171020

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1241886

Country of ref document: HK